Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001381017 | SCV001579268 | pathogenic | Biotinidase deficiency | 2020-01-02 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (ExAC no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the BTD protein. Other variant(s) that disrupt this region (p.Leu498Phefs*13) have been determined to be pathogenic (PMID: 17382128, 29359854, 19728141). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has been observed in individuals with a positive newborn screening result for BTD-related disease (PMID: 29353266) This sequence change results in a premature translational stop signal in the BTD gene (p.Trp140*). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 404 amino acids of the BTD protein. |
Baylor Genetics | RCV001381017 | SCV004211474 | pathogenic | Biotinidase deficiency | 2023-03-09 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001381017 | SCV005660268 | pathogenic | Biotinidase deficiency | 2024-06-12 | criteria provided, single submitter | clinical testing |